Dr. Mark Kowalski, M.D., Ph.D., has been named chief medical officer and senior vice president of Tekmira Pharmaceuticals. The newly created position is intended to defines Tekmira’s focus on RNAi-based therapeutic products, including oncology treatment TKM-PLK1 and TKM-Ebola. Dr. Kowalski has 25 years of experience in academic and clinical research, as well as clinical drug development through his work at major pharmaceutical and biotechnology companies, where he has led product developm...